Cargando…

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy

Angiogenesis describes the formation of blood vessels from an existing vascular network. Anti-angiogenic drugs that target tumor blood vessels have become standard of care in many cancer entities. Though very promising results in preclinical evaluation, anti-angiogenic treatments fell short of expec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiffmann, Lars M., Bruns, Christiane J., Schmidt, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162757/ https://www.ncbi.nlm.nih.gov/pubmed/35664794 http://dx.doi.org/10.3389/fonc.2022.897927

Ejemplares similares

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Tumor Microenvironment of Esophageal Cancer
por: Schiffmann, Lars M., et al.
Publicado: (2021)

The role of tumor microenvironment in resistance to anti-angiogenic therapy
por: Ma, Shaolin, et al.
Publicado: (2018)

Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
por: D'Aniello, Carmine, et al.
Publicado: (2019)

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022)

Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment
por: Licarete, Emilia, et al.
Publicado: (2020)

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
por: Xiao, Mingshu, et al.
Publicado: (2022)

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma
por: Fuselier, Camille, et al.
Publicado: (2021)

Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2013)

Editorial: Tumor Microenvironment and Resistance to Current Therapies
por: Lasfar, Ahmed, et al.
Publicado: (2019)

The role of angiogenic growth factors in the immune microenvironment of glioma
por: Ge, Zhengmao, et al.
Publicado: (2023)

Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression
por: Link, Wolfgang, et al.
Publicado: (2021)

Mechanical and metabolic interplay in the brain metastatic microenvironment
por: Onwudiwe, Killian, et al.
Publicado: (2022)

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
por: Yang, Zhengyang, et al.
Publicado: (2022)

Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
por: Saoudi González, Nadia, et al.
Publicado: (2022)

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential
por: Lahooti, Behnaz, et al.
Publicado: (2021)

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
por: Czajka-Francuz, Paulina, et al.
Publicado: (2023)

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
por: Xu, Donghan, et al.
Publicado: (2023)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
por: Chan, Anissa S. H., et al.
Publicado: (2022)

Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins
por: Zhu, Peng-Fei, et al.
Publicado: (2021)

IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Rizzo, Mimma, et al.
Publicado: (2022)

Trends and Challenges in Tumor Anti-Angiogenic Therapies
por: Jászai, József, et al.
Publicado: (2019)

Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
por: Wegiel, Barbara, et al.
Publicado: (2018)

Differences in Tumor Immune Microenvironment in Metastatic Sites of Breast Cancer
por: Lee, Hyunjong, et al.
Publicado: (2021)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Tumor microenvironment in non-melanoma skin cancer resistance to photodynamic therapy
por: Cerro, Paulina A., et al.
Publicado: (2022)

Editorial: Therapy resistance in tumor microenvironment: metabolic reprogramming and purinergic signaling
por: Zanoni, Michele, et al.
Publicado: (2023)

The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
por: Barillari, Giovanni
Publicado: (2020)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment
por: Zhang, Li, et al.
Publicado: (2023)

Editorial: Microenvironment and therapy-resistance in leukemias
por: Friedmann, Rachel, et al.
Publicado: (2023)

Extracellular vesicles in tumor angiogenesis and resistance to anti‐angiogenic therapy
por: Ye, Zi‐Wu, et al.
Publicado: (2023)

Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
por: Cren, Pierre-Yves, et al.
Publicado: (2020)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Evaluation of (18)F-FMISO PET and (18)F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy
por: Lee, Sze Ting, et al.
Publicado: (2021)

Mechanisms of resistance to anti-angiogenic treatments
por: Pezzella, Francesco
Publicado: (2019)

Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma
por: Malo, Courtney S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5jg9iecscjjc83gms06njrut04